Asterion Announces Appointment of Mr. Peter Ryan as Director of Development (Australia)
Vancouver, British Columbia: Asterion Cannabis Inc. (“Asterion” or the “Company”), announces the appointment of Mr. Peter Ryan, PhD, BEng, BBus, MProMan, as the Director of Development (Australia).
Mr. Ryan is an executive engineer and business leader with a track record of delivering strong operational results in organisations operating within the infrastructure and construction industry. Mr. Ryan’s career spans over 25 years, during which time he has worked throughout Australia, South East Asia and the South Pacific and has overseen the completion of a diversified portfolio of complex projects in numerous market sectors, including in the health, infrastructure, building, renewable energy and manufacturing sectors.
Mr. Ryan has shown the ability to develop and lead successful businesses that are underpinned by clear strategic vision and strong corporate governance. Previously, Mr. Ryan was an executive of Leighton Contractors, where he was responsible for delivering over $5 billion in projects across ten market sectors. Most recently, Mr. Ryan was the Managing Director of WBHO’s Australian infrastructure business, where he led the transformation of the company’s Australian operations into a diversified national infrastructure and construction business.
“We are very pleased to have Mr. Ryan join our team,” stated Stephen Van Deventer, Chairman and CEO of Asterion. “With his extensive experience working in large-scale infrastructure and construction throughout Australia, South East Asia and the South Pacific, his proven ability to deliver operational results will be ideal for Asterion as we work to bring our Toowoomba cannabis facility into production.”
Mr. Ryan commented “I am excited to be associated with Asterion to develop its world class Toowoomba cannabis production facility, which will create employment opportunities for the local community and support the advancement of medical cannabis globally.”
Asterion is a Canadian medicinal cannabis company with operations in Australia, specializing in medical cannabis with a goal of becoming an industry leader in next generation cannabis products. Asterion is focused on the future of advanced agriculture and aims to produce the highest quality genetically uniform cannabis strains, at an affordable price.
Asterion is led by a team of highly experienced executives with over 120 years of combined experience in medical cannabis, renewable energy, capital markets, and other highly relevant sectors across North America, Oceania, Europe, Africa and Asia.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chief Executive Officer
For further information, please contact:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the construction of the Toowoomba cannabis production facility, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding the Company, including that the Company will be able to obtain the financing and regulatory approvals and licences needed to build the Toowoomba cannabis production facility and to carry out its planned future activities. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, but not limited to, the inability of the Company (or its Australian subsidiary) to obtain the required approvals and licences for the construction and operation of the Toowoomba cannabis production facility, execute its proposed business plans and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or medical cannabis industry and delays in obtaining governmental and regulatory approvals, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.